Login to Your Account



Clinic Roundup


Thursday, May 16, 2013
• OncoMed Pharmaceuticals Inc., of Redwood City, Calif., began a Phase Ib/II trial of its anti-Notch2/3 antibody (OMP-59R5), triggering an $8 million milestone payment from GlaxoSmithKline plc, of London.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription